Jingzhi Guanxin Oral Liquids Attenuate Atherosclerotic Coronary Heart Disease via Modulating Lipid Metabolism and PPAR-Related Targets.

MLA

Wang, Xinning, et al. “Jingzhi Guanxin Oral Liquids Attenuate Atherosclerotic Coronary Heart Disease via Modulating Lipid Metabolism and PPAR-Related Targets.” Pharmaceuticals (14248247), vol. 17, no. 6, June 2024, p. 784. EBSCOhost, https://doi.org/10.3390/ph17060784.

APA

Wang, X., Hu, T., Jiang, Y., He, Y., Li, P., Peng, W., Wang, Y., & Su, W. (2024). Jingzhi Guanxin Oral Liquids Attenuate Atherosclerotic Coronary Heart Disease via Modulating Lipid Metabolism and PPAR-Related Targets. Pharmaceuticals (14248247), 17(6), 784. https://doi.org/10.3390/ph17060784

Chicago

Wang, Xinning, Tao Hu, Yuliang Jiang, Yan He, Peibo Li, Wei Peng, Yonggang Wang, and Weiwei Su. 2024. “Jingzhi Guanxin Oral Liquids Attenuate Atherosclerotic Coronary Heart Disease via Modulating Lipid Metabolism and PPAR-Related Targets.” Pharmaceuticals (14248247) 17 (6): 784. doi:10.3390/ph17060784.